These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
759 related articles for article (PubMed ID: 27509102)
1. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. Germain DP; Hughes DA; Nicholls K; Bichet DG; Giugliani R; Wilcox WR; Feliciani C; Shankar SP; Ezgu F; Amartino H; Bratkovic D; Feldt-Rasmussen U; Nedd K; Sharaf El Din U; Lourenco CM; Banikazemi M; Charrow J; Dasouki M; Finegold D; Giraldo P; Goker-Alpan O; Longo N; Scott CR; Torra R; Tuffaha A; Jovanovic A; Waldek S; Packman S; Ludington E; Viereck C; Kirk J; Yu J; Benjamin ER; Johnson F; Lockhart DJ; Skuban N; Castelli J; Barth J; Barlow C; Schiffmann R N Engl J Med; 2016 Aug; 375(6):545-55. PubMed ID: 27509102 [TBL] [Abstract][Full Text] [Related]
2. Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS). Lenders M; Nordbeck P; Kurschat C; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; Stumpfe K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E Clin Pharmacol Ther; 2020 Aug; 108(2):326-337. PubMed ID: 32198894 [TBL] [Abstract][Full Text] [Related]
3. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study. Germain DP; Nicholls K; Giugliani R; Bichet DG; Hughes DA; Barisoni LM; Colvin RB; Jennette JC; Skuban N; Castelli JP; Benjamin E; Barth JA; Viereck C Genet Med; 2019 Sep; 21(9):1987-1997. PubMed ID: 30723321 [TBL] [Abstract][Full Text] [Related]
5. Migalastat: A Review in Fabry Disease. McCafferty EH; Scott LJ Drugs; 2019 Apr; 79(5):543-554. PubMed ID: 30875019 [TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Feldt-Rasmussen U; Hughes D; Sunder-Plassmann G; Shankar S; Nedd K; Olivotto I; Ortiz D; Ohashi T; Hamazaki T; Skuban N; Yu J; Barth JA; Nicholls K Mol Genet Metab; 2020; 131(1-2):219-228. PubMed ID: 33012654 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study. Narita I; Ohashi T; Sakai N; Hamazaki T; Skuban N; Castelli JP; Lagast H; Barth JA Clin Exp Nephrol; 2020 Feb; 24(2):157-166. PubMed ID: 31889231 [TBL] [Abstract][Full Text] [Related]
8. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410 [TBL] [Abstract][Full Text] [Related]
18. Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). Lenders M; Nordbeck P; Kurschat C; Eveslage M; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; von Cossel K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):272-281. PubMed ID: 35512362 [TBL] [Abstract][Full Text] [Related]
19. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data. Riccio E; Zanfardino M; Ferreri L; Santoro C; Cocozza S; Capuano I; Imbriaco M; Feriozzi S; Pisani A; Eur J Hum Genet; 2020 Dec; 28(12):1662-1668. PubMed ID: 32647377 [TBL] [Abstract][Full Text] [Related]
20. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. Nakao S; Takenaka T; Maeda M; Kodama C; Tanaka A; Tahara M; Yoshida A; Kuriyama M; Hayashibe H; Sakuraba H N Engl J Med; 1995 Aug; 333(5):288-93. PubMed ID: 7596372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]